AU2015252184B2 - A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline - Google Patents
A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline Download PDFInfo
- Publication number
- AU2015252184B2 AU2015252184B2 AU2015252184A AU2015252184A AU2015252184B2 AU 2015252184 B2 AU2015252184 B2 AU 2015252184B2 AU 2015252184 A AU2015252184 A AU 2015252184A AU 2015252184 A AU2015252184 A AU 2015252184A AU 2015252184 B2 AU2015252184 B2 AU 2015252184B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- sap
- disease
- formula
- amyloidosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1407506.3 | 2014-04-29 | ||
| GBGB1407506.3A GB201407506D0 (en) | 2014-04-29 | 2014-04-29 | Novel compound |
| PCT/EP2015/058998 WO2015165833A1 (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015252184A1 AU2015252184A1 (en) | 2016-10-27 |
| AU2015252184B2 true AU2015252184B2 (en) | 2017-11-02 |
Family
ID=50972033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015252184A Ceased AU2015252184B2 (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9701668B2 (enExample) |
| EP (1) | EP3137457B1 (enExample) |
| JP (1) | JP6445046B2 (enExample) |
| KR (1) | KR20160145617A (enExample) |
| CN (1) | CN106459016B (enExample) |
| AR (1) | AR100204A1 (enExample) |
| AU (1) | AU2015252184B2 (enExample) |
| BR (1) | BR112016025129A2 (enExample) |
| CA (1) | CA2947060C (enExample) |
| CL (1) | CL2016002721A1 (enExample) |
| CR (1) | CR20160508A (enExample) |
| DO (1) | DOP2016000292A (enExample) |
| EA (1) | EA032129B1 (enExample) |
| ES (1) | ES2731253T3 (enExample) |
| GB (1) | GB201407506D0 (enExample) |
| IL (2) | IL248249A0 (enExample) |
| MA (1) | MA39406B1 (enExample) |
| MX (1) | MX2016014246A (enExample) |
| MY (1) | MY191088A (enExample) |
| PE (1) | PE20161558A1 (enExample) |
| PH (1) | PH12016502006B1 (enExample) |
| SG (1) | SG11201608371RA (enExample) |
| TW (1) | TWI676624B (enExample) |
| UA (1) | UA119871C2 (enExample) |
| UY (1) | UY36098A (enExample) |
| WO (1) | WO2015165833A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201518950D0 (en) | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051836A1 (en) * | 2001-12-14 | 2003-06-26 | F. Hoffmann-La Roche Ag | Prodrugs to d-prolines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT915088E (pt) | 1997-10-31 | 2003-01-31 | Hoffmann La Roche | Derivados de d-prolina |
| EP1636240A1 (en) | 2003-06-05 | 2006-03-22 | Pfizer Products Inc. | Beta-lactamase inhibitor prodrug |
| GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| EP1870412A4 (en) | 2005-04-12 | 2009-12-30 | Meiji Seika Kaisha | 2-THIOETHENYLCARBAPENEM DERIVATIVE |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
-
2014
- 2014-04-29 GB GBGB1407506.3A patent/GB201407506D0/en not_active Ceased
-
2015
- 2015-04-27 KR KR1020167029703A patent/KR20160145617A/ko not_active Ceased
- 2015-04-27 JP JP2016565212A patent/JP6445046B2/ja not_active Expired - Fee Related
- 2015-04-27 CN CN201580023347.0A patent/CN106459016B/zh not_active Expired - Fee Related
- 2015-04-27 CA CA2947060A patent/CA2947060C/en active Active
- 2015-04-27 EA EA201692185A patent/EA032129B1/ru not_active IP Right Cessation
- 2015-04-27 AU AU2015252184A patent/AU2015252184B2/en not_active Ceased
- 2015-04-27 MA MA39406A patent/MA39406B1/fr unknown
- 2015-04-27 US US14/787,608 patent/US9701668B2/en not_active Expired - Fee Related
- 2015-04-27 ES ES15720312T patent/ES2731253T3/es active Active
- 2015-04-27 TW TW104113338A patent/TWI676624B/zh not_active IP Right Cessation
- 2015-04-27 MX MX2016014246A patent/MX2016014246A/es active IP Right Grant
- 2015-04-27 MY MYPI2016703952A patent/MY191088A/en unknown
- 2015-04-27 CR CR20160508A patent/CR20160508A/es unknown
- 2015-04-27 EP EP15720312.6A patent/EP3137457B1/en active Active
- 2015-04-27 PE PE2016001934A patent/PE20161558A1/es unknown
- 2015-04-27 UA UAA201612105A patent/UA119871C2/uk unknown
- 2015-04-27 SG SG11201608371RA patent/SG11201608371RA/en unknown
- 2015-04-27 UY UY0001036098A patent/UY36098A/es not_active Application Discontinuation
- 2015-04-27 BR BR112016025129A patent/BR112016025129A2/pt not_active Application Discontinuation
- 2015-04-27 WO PCT/EP2015/058998 patent/WO2015165833A1/en not_active Ceased
- 2015-04-27 AR ARP150101262A patent/AR100204A1/es active IP Right Grant
-
2016
- 2016-10-09 IL IL248249A patent/IL248249A0/en active IP Right Grant
- 2016-10-10 PH PH12016502006A patent/PH12016502006B1/en unknown
- 2016-10-26 CL CL2016002721A patent/CL2016002721A1/es unknown
- 2016-10-28 DO DO2016000292A patent/DOP2016000292A/es unknown
-
2017
- 2017-06-01 US US15/610,984 patent/US9873686B2/en active Active
- 2017-12-11 US US15/837,297 patent/US10597385B2/en active Active
-
2020
- 2020-12-01 IL IL279120A patent/IL279120A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051836A1 (en) * | 2001-12-14 | 2003-06-26 | F. Hoffmann-La Roche Ag | Prodrugs to d-prolines |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI638831B (zh) | 胜肽化合物 | |
| US9737505B2 (en) | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | |
| JP2018177788A (ja) | Ｎｔｃｐ阻害剤によるアテローム性動脈硬化、原発性胆汁性肝硬変およびｎｒｌｐ３インフラマソーム関連疾患の治療 | |
| US10597385B2 (en) | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | |
| CN117940407A (zh) | 降低免疫不耐受和治疗自身免疫病症的组合物和方法 | |
| AU2015237253A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
| WO2023165459A1 (en) | Compounds as sars-cov-2 inhibitors | |
| US10328052B2 (en) | D-proline derivatives as SAP depleting agent | |
| CN114025766A (zh) | 用于抑制gapdh的噁噻嗪化合物 | |
| EP4192843A1 (en) | Peptides able to bind angiotensin-converting enzyme 2 (ace2) and medical uses thereof | |
| EP4178945B1 (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| HK40067738A (en) | Oxathiazin compounds for inhibiting gapdh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |